Cantor Fitzgerald Reaffirms “Overweight” Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Cantor Fitzgerald restated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $28.00 price target on the biopharmaceutical company’s stock.

MRNS has been the topic of several other research reports. Royal Bank of Canada reissued an outperform rating and set a $24.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, March 6th. HC Wainwright reissued a buy rating and set a $27.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, March 26th. Oppenheimer reissued a market perform rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Finally, StockNews.com cut shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $21.21.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $7.52 on Wednesday. Marinus Pharmaceuticals has a 52-week low of $5.57 and a 52-week high of $11.26. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68. The firm’s fifty day moving average is $9.24 and its two-hundred day moving average is $8.59.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same period last year, the firm earned ($0.76) EPS. Equities analysts predict that Marinus Pharmaceuticals will post -2.43 earnings per share for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. purchased a new stake in Marinus Pharmaceuticals during the second quarter worth about $45,000. Quantbot Technologies LP purchased a new stake in Marinus Pharmaceuticals during the first quarter worth about $40,000. FMR LLC increased its stake in Marinus Pharmaceuticals by 1,887.9% during the first quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 4,210 shares during the period. BluePath Capital Management LLC purchased a new stake in Marinus Pharmaceuticals during the third quarter worth about $38,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Marinus Pharmaceuticals by 383.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 5,003 shares during the period. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.